MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
Medical University of Vienna
Viena, AustriaPublicacións en colaboración con investigadores/as de Medical University of Vienna (29)
2023
-
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
European Journal of Cancer, Vol. 184, pp. 48-59
2022
-
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 282-293
-
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial
Frontiers in Oncology, Vol. 12
-
Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients
European Journal of Cancer, Vol. 166, pp. 185-201
-
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Cancer Treatment Reviews, Vol. 111
-
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer, Vol. 168, pp. 12-24
2021
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581
-
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer
Cancers, Vol. 13, Núm. 17
-
Expected medium- And long-term impact of the COVID-19 outbreak in oncology
JCO Global Oncology, Vol. 7, pp. 162-172
-
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Clinical Breast Cancer, Vol. 21, Núm. 1, pp. 80-91.e7
-
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
European Journal of Cancer, Vol. 156, pp. 70-82
-
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 14, pp. 1518-1530
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
-
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Oncological care organisation during COVID-19 outbreak
ESMO Open, Vol. 5, Núm. 4
2019
-
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: Longitudinal analyses from the randomized phase III ExteNET trial
Annals of Oncology, Vol. 30, Núm. 4, pp. 567-574
-
PIK3CA alterations and benefit with neratinib: Analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
Breast Cancer Research, Vol. 21, Núm. 1
-
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
Breast Cancer Research and Treatment, Vol. 176, Núm. 2, pp. 377-386
2017
-
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700